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STUDY PROTOCOL Open Access
Integrating addiction treatment into primary care
using mobile health technology: protocol for an
implementation research study
Andrew R Quanbeck1*, David H Gustafson1, Lisa A Marsch2, Fiona McTavish1, Randall T Brown3,
Marie-Louise Mares4, Roberta Johnson1, Joseph E Glass5, Amy K Atwood1 and Helene McDowell1
Abstract
Background: Healthcare reform in the United States is encouraging Federally Qualified Health Centers and other
primary-care practices to integrate treatment for addiction and other behavioral health conditions into their
practices. The potential of mobile health technologies to manage addiction and comorbidities such as HIV in these
settings is substantial but largely untested. This paper describes a protocol to evaluate the implementation of an
E-Health integrated communication technology delivered via mobile phones, called Seva, into primary-care settings.
Seva is an evidence-based system of addiction treatment and recovery support for patients and real-time caseload
monitoring for clinicians.
Methods/Design: Our implementation strategy uses three models of organizational change: the Program Planning
Model to promote acceptance and sustainability, the NIATx quality improvement model to create a welcoming
environment for change, and Rogers’s diffusion of innovations research, which facilitates adaptations of innovations
to maximize their adoption potential. We will implement Seva and conduct an intensive, mixed-methods
assessment at three diverse Federally Qualified Healthcare Centers in the United States. Our non-concurrent
multiple-baseline design includes three periods — pretest (ending in four months of implementation preparation),
active Seva implementation, and maintenance — with implementation staggered at six-month intervals across sites.
The first site will serve as a pilot clinic. We will track the timing of intervention elements and assess study outcomes
within each dimension of the Reach, Effectiveness, Adoption, Implementation, and Maintenance framework,
including effects on clinicians, patients, and practices. Our mixed-methods approach will include quantitative (e.g.,
interrupted time-series analysis of treatment attendance, with clinics as the unit of analysis) and qualitative (e.g., staff
interviews regarding adaptations to implementation protocol) methods, and assessment of implementation costs.
Discussion: If implementation is successful, the field will have a proven technology that helps Federally Qualified
Health Centers and affiliated organizations provide addiction treatment and recovery support, as well as a proven
strategy for implementing the technology. Seva also has the potential to improve core elements of addiction
treatment, such as referral and treatment processes. A mobile technology for addiction treatment and
accompanying implementation model could provide a cost-effective means to improve the lives of patients with
drug and alcohol problems.
Trial registration: ClinicalTrials.gov (NCT01963234).
Keywords: Primary care integration, Systems change, E-Health, RE-AIM framework
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Background
Context
This paper describes the protocol for a study on imple-
menting mobile-health technology in primary care. The
study is funded by the United States’ National Institute
on Drug Abuse as part of a request for proposals aimed
at integrating addiction treatment into primary care. Al-
though numerous smartphone applications exist that
address many health problems, primary care clinicians
do not commonly incorporate mobile technology into
patient care [1]. One reason is that very few smartphone
applications have been proven in rigorous trials of ef-
fectiveness. Even if an application does have a reliable
evidence base, it must still demonstrate its value to vari-
ous stakeholders if it is to be widely used. Patients must
see value in the application or they are likely to stop
using it. Clinicians must find it useful to incorporate it
in day-to-day clinical management. Finally, clinic ad-
ministrators must find that the application works both
clinically and financially to support its use by patients
and staff.
Our study focuses on Federally Qualified Health Cen-
ters (FQHCs) in the United States, community-based
organizations that provide primary care and preventive
health services to patients regardless of their ability to
pay. FQHCs (and U.S. primary-care practices in general)
are increasingly being encouraged by healthcare reform
to integrate treatment for addiction and behavioral
health into their practices. HIV testing and prevention
efforts are particularly important for the health of men
and women who use illicit drugs because they are at
higher risk than the general population for acquiring
HIV [2,3]. But transforming primary care to address ad-
diction and HIV will likely add to the work of clinicians,
many of whom already feel overburdened. Previous at-
tempts to integrate addiction treatment into primary
care have largely relied on labor-intensive solutions (e.g.,
adding more staff or having staff do tasks differently), with
mixed results [4].
Our premise is that mobile health technology holds
great promise for FQHCs to reach this complex patient
population. More than two-thirds of individuals with
substance use disorders (SUDs) have had contact with a
primary-care provider in the previous six months [5], for
reasons that may or may not relate to their SUD [6]. But
primary-care providers frequently do not screen for or
treat SUDs, even though recovery support can be effect-
ively administered in primary care [6,7]. Administering
recovery support requires that clinicians receive support
and training in addiction, which are uncommon partly
because of the traditional separation of addiction treat-
ment from primary care [8-10]. Technology may help
address these problems. People with addictions tend to
view technology favorably [11]. They acknowledge more
drug use and psychiatric symptoms online than in face-
to-face interviews [12]. A recent review found positive
outcomes in 29 of 32 randomized trials using personal
computers and cell phones for managing chronic dis-
eases [13]. While some information technologies have
proven efficacious, penetration into practice has been
slow [14]. The potential of mobile health technologies to
manage chronic diseases in FQHCs is substantial, but
remains largely untested.
The mobile-health technology
The integrated system we have developed is an E-Health
integrated communication technology for patients with
addiction called Seva (say’-va; a Sanskrit word for self-
less caring). Seva consists of treatment and recovery
support elements. The treatment component is based
on the Therapeutic Education System (TES), a web- and
mobile-based curriculum for addiction treatment with 65
interactive, multimedia, skill-building modules, including
basic cognitive behavioral recovery support skills (e.g.,
refusing drugs, managing thoughts about drug use), life
re-structuring skills (e.g., increasing recreational activ-
ities), and skills for preventing HIV, hepatitis, and sexu-
ally transmitted infections. Each module ends with a
quiz structured to ensure mastery of key content and
skills. TES uses interactive videos to create experiential
learning environments that help patients learn modeled
behaviors (e.g., progressive muscle relaxation). Random-
ized trials have found that TES is as efficacious as behav-
ioral therapy delivered by therapists and is superior to
standard substance abuse treatment [15]; that it increases
HIV prevention knowledge and self-reported risk for HIV
[16]; and when it partially replaces clinician-delivered care
in methadone treatment, it also improves opioid abstin-
ence rates [17].
Seva’s recovery support elements are based on A-CHESS,
an evidence-based smartphone program designed to help
people in recovery from drug and alcohol addiction pre-
vent relapse. A-CHESS helps patients meet the challenges
they often face, such as loneliness and isolation, transpor-
tation, managing the treatment regimen, and getting in-
formal support. A-CHESS also addresses issues such as
cravings and insufficient coping skills in high-risk situa-
tions. A-CHESS is based on research on the principles of
effective continuing care for substance use disorders (long
duration, assertive outreach, monitoring, prompts, action
planning, peer and family support, and case management).
The research team that developed A-CHESS has studied
and designed similar systems that have been effective for
patients suffering from lung cancer, breast cancer, asthma,
and HIV [2,3,18-36]. In a randomized trial of patients
discharged from residential addiction treatment, patients
with A-CHESS had 57% fewer risky drinking days than
patients in the control group [37].
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Although Seva was built from two existing programs,
TES and A-CHESS, the Seva user experiences one seam-
less system with many links between elements. For ex-
ample, upon completing a skill-building module, the
patient may be shown a link to a discussion group where
peers are discussing the topic of the module, and pro-
vided links to further information on the topic. Similarly,
patients whose responses to check-in items indicate a
potential problem may see a link to skill-building related
to that problem, or be shown personal stories from other
patients who have dealt with the same problem. Patient-
entered data are also uploaded and presented via a web-
based dashboard that FQHC clinicians can use to monitor
the status of their Seva users. The dashboard includes
items that patients self-report using their mobile devices,
such as sleep troubles and relationship problems that may
signal an imminent relapse; whether the patient has
attended recovery meetings or completed other elements
of the treatment plan; and the patient’s relapse risk and
protection factors. The dashboard can be customized for
each clinic to display indicators that clinicians deem im-
portant for clinical decision-making.
Study focus: implementation
Because Seva has an established evidence base, this research
focuses mainly on implementation and organizational
impact; some patient-level outcomes are included, but
they will be examined in the aggregate. Our goal is to
implement a system that has already proven effective in
specialty addiction treatment in primary-care settings.
The implementation model we are testing (detailed below)
is distinguished by several characteristics: an effort to ac-
tively prepare the environment for implementation; the
use of an organizational coach; the use of rapid-cycle tests;
and an early, specific effort to address sustainability. The
implementation model is rooted in the field of systems
engineering, a multi-disciplinary field that integrates
concepts from psychology, economics, social science, and
statistics. The implementation model reflects the multi-
disciplinary ethic of systems engineering.
We will study organizational change resulting from
implementing Seva in 3 FQHCs over a three-year period.
We will study elements of our implementation model by
using mixed-methods analysis. Our study seeks answers
to three broad research questions: how can Seva be imple-
mented in primary care settings efficiently and effectively;
to what extent do patients and staff accept and use Seva;
and how does Seva affect clinical care for patients and
staff?
Methods/Design
Implementation model
Our implementation strategy combines three evidence-
based organizational change strategies: the Program
Planning Model (PPM) [38,39], the NIATx quality
improvement model [40,41], and core concepts from
Rogers’s diffusion of innovations research [42]. The
PPM comes from the literature of organizational be-
havior; NIATx, from systems engineering; and Rogers,
from community-based diffusion. The PPM addresses
interpersonal, organizational and environmental variables
that promote sustainability. By focusing on socio-political
aspects of change in community-based organizations, use
of the PPM has led to greater community acceptance than
seen in comparison groups [38,39]. The NIATx model,
an extensively evaluated and widely adopted organi-
zational change model in addiction treatment, provides
an evidence-based approach to implementation by opti-
mizing processes that create a welcoming environment
for change [40,41]. Rogers’s diffusion of innovations re-
search identified characteristics of innovations associ-
ated with successful implementation and sustainability
[42]. Rogers’s research complements the NIATx model
by emphasizing ways to adapt an innovation for a spe-
cific setting, thus maximizing its adoption potential.
Combined, these strategies make up the implementation
model shown in Figure 1.
The model has 4 phases: i) ‘Initiate’ involves bringing
together and training key people at each site; ii) ‘Prepare’
ensures that the FQHC environment is welcoming to
Seva, the implementation plan adapts to the unique
characteristics of the FQHC, and the technology is de-
veloped to maximize its chance of success; iii) ‘Improve’
involves conducting a series of rapid-cycle tests of ideas
that emerge from earlier phases; and iv) ‘Implement’ in-
volves using, monitoring and sustaining the technology.
Organizational coaching will play a key role in helping
clinics implement Seva successfully. We recently com-
pleted a randomized trial in 201 addiction treatment
agencies in which coaching proved to be the most cost-
effective approach to quality improvement among sev-
eral strategies tested [43]. An implementation coach will
work with each FQHC to advise, encourage and monitor
progress.
Settings for implementation
We worked with the National Association of Community
Health Centers to identify a set of FQHCs with established
electronic health records. We focused on FQHCs with
electronic health records because healthcare reform has
been pushing FQHCs in this direction, and we believe it
will be important to understand how Seva relates to exist-
ing clinic technology. From the pool of FQHCs that met
these criteria, we selected an FQHC affiliated with the
University of Wisconsin as our first implementation site;
as a second site, a relatively small, rural, freestanding
FQHC with integrated behavioral health services (includ-
ing addiction treatment); and as a third site, an urban
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FQHC that serves a largely minority population. In select-
ing sites, we strove to maximize diversity in both patient
populations and organizational structures to better under-
stand how environment affects implementation. We in-
cluded only three FQHCs in order to conduct an
intensive, mixed-methods assessment at each clinic, which
we believe will be more informative for the ultimate pur-
pose of dissemination than randomizing a larger sample of
organizations and studying implementation at a surface
level.
Timeline
Data will be collected from each FQHC for 48 months
using a combination of data sources, including electronic
health records, staff surveys/interviews, and patient sur-
veys/interviews. We are collecting staff survey data every 6
months for 36 months, patient survey data every 6 months
for 18 months, and aggregated EHR data for 48 months to
cover the full time frame from the beginning of the pretest
period at FQHC 1 to the end of the posttest period at
the FQHC 3. Figure 2 shows more information about
Figure 1 Implementation model.
Activity    Month 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60
Integrate technology
Update technology
Formalize FQHC plans
Prepare environments
Prepare implementation
FQHC 1
FQHC 2
FQHC 3
Collect qualitative data
Collect cost data
Clean & prepare data
Analyze results Early analysis period
Baseline Sustainability
Final analysis period
Disseminate Early publications Final publications
Implementation
Figure 2 Project timeline.
Quanbeck et al. Implementation Science 2014, 9:65 Page 4 of 11
http://www.implementationscience.com/content/9/1/65
the project timeline. Retrospective data collection will take
place during the pretest period, using aggregated patient
data from clinics’ electronic health records. During the
pretest period, sites will also seek to identify potential pa-
tient candidates for recruitment. Full-scale implementa-
tion occurs during the subsequent 12 months, during
which the sites receive coaching and actively recruit pa-
tients to use Seva. The sites will continue to be monitored
during a post-test/sustainability period. During this period,
sites may continue recruiting patients to use Seva, but
without grant funding for phone/internet support or
organizational coaching.
Coaching for organizational change
The organizational coach for the first (pilot) site will be
a member of the research team with extensive experi-
ence in organizational coaching. The next two sites will
be coached by a physician from the pilot site, who will
share firsthand experience in implementing Seva with
subsequent clinics. Each site will have a designated
‘change leader’, a clinical leader at the site who is the
point of contact with the coach and will coordinate im-
plementation activities at the clinic; a ‘site coordinator’,
a clinic employee who will enroll patients in the study
and manage the day-to-day operation of Seva; and a
‘change team’, a group of four to eight clinical and/or
administrative staff members who will help identify and
make the organizational changes necessary to implement
Seva. The coach will make an initial site visit during the
four-month period of active implementation preparation
to create a welcoming environment for Seva. During this
visit, the coach will conduct a walk-through [44] with
change team members (an exercise in which employees
experience the clinic as patients do, to reveal issues that
need to be addressed); a work flow assessment using
flow charting; and a technical assessment of data to be
gathered and procedures needed to conduct the study.
During this preparation period, the coach will also work
with the change leader to ensure that pre-test data are
collected; reviews of Seva are completed by clinical
teams and their concerns addressed; and barriers to im-
plementation rectified. After the initial site visit, for the
remainder of the implementation preparation period and
for the 12-month intervention period, the coach will have
monthly telephone conferences with clinic staff and email
correspondence as necessary to monitor implementation
progress and offer advice and feedback to the staff. The
coach and change leader will also work together to reduce
organizational barriers to implementation.
Study design
Our study uses a non-concurrent multiple-baseline design
in which the start of the intervention period is staggered
at the three sites by six months. The multiple-baseline
design provides the intervention to all participants, but
isolates the independent variable by introducing the inter-
vention at specified points. Using the clinic as the unit of
analysis, this single-subject approach will closely track the
timing of intervention elements and repeatedly measure
outcomes at the organizational level, including aggregated
effects on clinicians, patients and practices. After pilot
testing Seva at the first FQHC and improving Seva and
the overall implementation strategy, we will introduce
Seva at the second FQHC and then, six months later, at
the third FQHC. Each FQHC acts as its own pretest con-
trol. During the 48-month data collection period, core
organizational indicators will be measured via a staff sur-
vey (administered every 6 months) and the clinics’ elec-
tronic health records (aggregated across patients). While
the non-concurrent multiple-baseline design may not pro-
vide as strong a basis for causal inference as a large RCT,
we believe it is the appropriate design for evaluating the
organizational impact of a system that has already been
shown effective in RCTs of patients [45]. We will also col-
lect a set of standard CHESS/TES measures via a patient
survey for comparison to previous studies that tested these
technologies in RCTs, and to conduct exploratory ana-
lyses. The patient survey also provides supplemental
clinical information not routinely collected in the clinics
(e.g., addiction severity, quality of life, etc.).
Evaluation framework
Our primary focus is to study how Seva is implemented in
three FQHCs. In the process, we hope to generate insights
on how Seva can be most helpful to organizations, staff
and patients, thereby informing implementation processes
in other FQHCs. Our evaluation includes patient, clin-
ician, and organization-level outcomes. To organize this
multifaceted evaluation, we use the RE-AIM framework
[46]. RE-AIM catalogs the quality, speed and impact of
efforts to translate research into practice by including
measures in five categories: reach, effectiveness, adop-
tion, implementation and maintenance. The measures
we will use are summarized in Table 1, followed by a brief
description of each dimension and selected outcomes.
Reach
In assessing reach, we will determine how many patients
are eligible to use Seva within each clinic, how many are
excluded, how many are invited to participate, and how
many enroll in the study. We will also study how quickly
patients are enrolled after the beginning of the enroll-
ment period. We will assess how representative Seva
enrollees are of the target population (substance using
patients within each clinic) by comparing users to the
target population on key clinical characteristics (e.g.,
treatment attendance, healthcare utilization). Qualitative
assessment will supplement our data collection on reach.
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Our goal is to understand how clinicians perceive or an-
ticipate which patients may benefit most from the sys-
tem, because — for budget reasons — not all patients
can have Seva, either in this study or in a broader dis-
semination. (In this study, we can offer Seva to a max-
imum of 100 patients per clinic.) For example, clinicians
may select patients to enroll who they think will be strong
models for other patients, or patients who have had many
relapses and may benefit from a different treatment
approach. As an implementation-focused study, we strive
not for random selection but instead encourage clinicians
to enroll patients for whom they believe Seva will be most
helpful.
Effectiveness
Our primary effectiveness outcome is substance use.
Other outcomes in the effectiveness domain will help us
understand the impact of Seva on patients’ quality of life,
Table 1 RE-AIM measures
Dimension Measure Source Research
question*
Frequency
Reach Number of Seva patients (eligible, excluded, enrolled) Patient survey 2 Pre
Characteristics of participating patients Patient survey 2 Pre
EHR 2 Continuous
Qualitative assessment- reach Interview- clinic director 1 Pre
Effectiveness No. patients screened for HIV EHR 3 Continuous
Healthcare utilization (hospitalizations, ER visits, and
residential addiction treatment)
Patient survey 3 0 m, 6 m, 12 m,
18 m
EHR 3 Continuous
Treatment attendance Patient survey 3 0 m, 6 m, 12 m,
18 m
EHR 3 Continuous
HIV risk behaviors Patient survey 3 0 m, 6 m, 12 m,
18 m
Substance use Seva 3 Weekly
Patient survey 3 0 m, 6 m, 12 m,
18m
Quality of life Patient survey 3 0 m, 6 m, 12 m,
18 m
Qualitative assessment - effectiveness Interview - clinic director 1 12 m
Adoption (setting) Characteristics of participating clinics vs. general FQHC
population
Publicly available uniform data
system reports for FQHCs
2 Pre
Readiness for implementation Staff survey 2 Pre, every 6 m
Adoption (staff) Use of Seva by staff (including characteristics) Seva log files 2 Continuous
Adoption (patient) Use of Seva by patients (including characteristics) Seva log files 2 Continuous
Adoption (staff
and patient)
Qualitative assessment- adoption Staff interviews 1 Pre, every 6 m
Patient interviews 1 12 m
Implementation Stages of Implementation Completion Staff interviews 1 Pre, every 6 m
Technology acceptance Staff survey 2 Pre, every 6 m
Adaptations to protocol during intervention period Staff interviews 1 Pre, every 6 m
Cost of intervention Staff interviews 1 Pre, every 6 m
Coach logs 1 Continuous
Qualitative assessment - implementation Interview with clinic director, coach 1 12 m
Maintenance Sustainability score Staff survey 1 Pre, every 6 m
Six-month follow-up on all effectiveness measures
(see above) and use of Seva
Seva, Patient survey, EHR 1, 2, 3 Various
Qualitative assessment - maintenance Interview - clinic director 1, 2 18 m
Source: Re-aim.org; Measuring the Use of the RE-AIM Model Dimension Items Checklist
*(1) How can Seva be implemented in primary care settings efficiently and effectively? (2) To what extent do patients and staff accept and use Seva? (3) How
does Seva affect clinical care for patients and staff?
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HIV risk behaviors, healthcare utilization, and treatment
attendance. We will also examine the extent to which
the system promotes an overall increase in the propor-
tion of substance-use patients screened for HIV. Health-
care utilization data (hospitalization, emergency room
visits, and in-patient psychiatric treatment) will also be
used in the cost analysis described below. Qualitative
assessment of effectiveness will take place through an
interview with the clinic director.
Adoption
In assessing adoption at the clinic level, we will report
how many FQHCs were approached to participate and
how many signed on to implement Seva. We will compare
organizational characteristics of participating FQHCs to
the more than 1,000 FQHCs in the United States, based
on public reports required of these organizations by the
federal government. We will gather qualitative data to as-
sess which aspects of organizational structure affect imple-
mentation. To assess adoption at the staff level, clinic site
coordinators will make a list of all staff members who see
potential substance-using patients in primary or behav-
ioral care, and invite these staff to complete surveys six
months prior to the implementation period and every
six months thereafter. The surveys include questions
on job function (i.e., physician, behavioral health staff,
or RN), which will allow us to assess how representa-
tive the respondents are of the clinic staff as a whole,
and the Readiness for Implementation Survey [47], an
instrument used to predict the adoption success of in-
formation technologies in healthcare. Staff members
and patients will take part in qualitative interviews to
supplement data provided in the surveys to assess
organizational barriers and facilitators related to imple-
mentation. We will analyze Seva log files to produce
metrics about patterns of system adoption and use by
patients and staff and assess the characteristics of indi-
viduals who use Seva most and least actively.
Implementation
To measure implementation progress, we will adapt our
implementation model into a specific implementation
plan (including timetables) for each clinic. We will em-
ploy the Stages of Implementation Completion model
[48] as a guide to assess the degree of implementation.
Each phase of the implementation completion model is
broken down into discrete tasks and events and pre-
sented as a checklist. We will assess whether each task/
event was implemented, and the length of time each
one took to implement. Starting at the beginning of the
implementation-planning period (four months prior to
implementation), the checklist will be reviewed and up-
dated every six months by the site coordinator in con-
junction with the implementation coach. Adaptations to
the protocol will be noted. We will also assess imple-
mentation costs (see below) and administer the Tech-
nology Acceptance Model [49], which helps explain
factors that influence the use of a new technology.
Qualitative assessment of the consistency of the inter-
vention will occur through interviews with the clinic
director and the implementation coach.
Maintenance
To assess maintenance, we will administer the British
National Health Service’s Sustainability Index [50]. The
Sustainability Index assesses factors associated with sus-
tainability potential, such as fit with organizational infra-
structure, clinical leadership engagement, and progress
monitoring. The Index also offers guidance, developed
by an international panel of experts, on overcoming weak-
nesses. Factors measured by the Sustainability Index, along
with those included in the Readiness for Implementation
Survey, will guide us in building a conceptual model of
barriers and facilitators to implementation. Assessing
maintenance at the individual level includes monitoring
of effectiveness measures (including substance use and
quality of life) at the 18-month mark, 6 months after
grant funding for phones and internet access ends. We
will examine data on Seva use at the staff and patient
levels to assess long-term maintenance of Seva. Qualita-
tive interviews with clinic directors will assess the de-
gree of institutionalization of Seva within organizations,
how Seva aligns with clinical business models, and
whether and how Seva was adapted after the active im-
plementation period to promote maintenance.
Analysis
We will use a mixed-method approach, using both
quantitative and qualitative methods, to assess our im-
plementation model. Our analysis follows guidelines for
mixed-methods research promulgated by the NIH Office
of Behavioral and Social Sciences Research [51]. Because
this is a study of the organizational impact of Seva, there
will be no single-patient analyses; all analyses will be
aggregated across patients.
Analysis of quantitative outcomes will proceed on three
fronts:
1. Descriptive statistics will be used to assess relevant
Reach outcomes.
2. Interrupted time series analysis will compare
selected Effectiveness and Maintenance outcomes
within a clinic before and after implementation. We
will assess whether our implementation model
promotes the successful installation and use of Seva
using linear regression models, with each analysis
having two time-series segments representing means
and slopes before and after implementation. A test
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of the regression coefficient for implementation (a
dichotomous variable indicating whether the time
point occurred before or after implementation) will
allow us to examine differences in the mean change
at implementation. Differences in slope from pre- to
post-implementation will be tested using the coefficient
for the implementation x month interaction, where
‘month’ is a continuous variable indicating the
month of measurement. Weighted least squares
analysis will be used to account for potential
differences in the number of patients or staff
reporting outcomes within each clinic across time.
Given the limited degrees of freedom, no covariates
will be included in the models.
3. Drawing from conventional approaches to
single-subject analysis, we will also compare selected
RE-AIM outcomes within and across the clinics
using data visualization [52] to determine whether
the shifts between intervention phases of the study
generated shifts in the level, trend, and variability of
performance [53]. This will allow us to evaluate the
immediacy, consistency and magnitude of the
observed effects [52].
The qualitative analysis is designed to:
1. Understand the environments in which Seva is
implemented, how Seva was tailored to fit each
environment, and the processes used to tailor Seva.
Focus groups and observational and interview data
will help us understand the environment and the
processes used to tailor Seva.
2. Provide insights into the quantitative results. We
will interview key stakeholders following each wave
of surveys. As within- and across-site findings
emerge, we will interview people who can help
inform the findings.
3. Understand the barriers to and facilitators of
implementing and sustaining Seva and how they
relate to outcomes. Key stakeholders will be asked to
reflect on reach, outcomes, adoption at the setting
level, staff participation, implementation, and
long-term effects.
4. Prompt informants to reflect upon how they might
advise a similar FQHC to integrate Seva.
We will collect, transcribe and analyze field notes
and interviews collected during each implementation
phase using AtlasTi. The qualitative analysis will follow
grounded theory to build a conceptual model of Seva’s
implementation. Two researchers will independently ana-
lyze interviews that represent different organization-level
stakeholders, and then meet to discuss and reconcile
differences in interpretation. Because Readiness for
Implementation Survey and Sustainability Index factors
are associated with adoption and sustainability, we will
include these factors as a priori themes, while seeking
new insights generated from the interviews. Researchers
will then code the remaining interviews, comparing
themes to distinguish different types of organizations
and conditions. To assure coding consistency, every fourth
interview will be double-coded. Significant inconsistencies
will be discussed and recoded. Finally, we will categorize
the themes into a working model.
Economic analysis
The sustainability of Seva will depend on both its effects
and its cost. Our cost analysis is conducted from the
adopting FQHC’s perspective and is intended to provide
estimates of the costs to implement and operate Seva
within an FQHC. The cost data collection instrument
follows guidelines for economic evaluation of implemen-
tation strategies [54]. It has been adapted from a cost
collection instrument we used in a previous quality im-
provement study [43]. The cost collection instrument
will track fixed costs of implementation, including sys-
tem development costs and research costs related to de-
velopment of the implementation strategy. The analysis
separates these one-time, fixed costs from variable costs
related to executing the implementation strategy, includ-
ing staff salaries (with fringe benefits) for training pa-
tients and attending project meetings. We will also track
operating costs, such as smartphones, monthly data
plans, and IT and clinician time for maintaining and im-
proving Seva. The cost data collection instrument will
be administered in semi-annual interviews with staff
members from the participating clinics and research
team during the intervention period. The coach will also
keep a detailed log of contacts with clinic staff to assess
staff participation during the intervention. We will esti-
mate the cost of implementing Seva by totaling the time
spent by coaches and clinicians during the implementa-
tion phase (using coach logs) and then multiplying the
hours by relevant wage rates by job classification. We
will add any non-personnel costs, such as travel to site
visits, the cost of teleconferencing services for follow-up
calls, etc. Any free services will be documented. Costs
incurred by patients are outside the scope of the
evaluation.
Evidence suggests that using Seva in a manner that
promotes integrative care will benefit FQHCs financially.
Research has shown that drug users who receive regular
drug abuse care with regular medical care are less likely
to be hospitalized than those who receive only regular
medical care alone, regular drug abuse care alone, or
neither [55]. For patients with substance-abuse-related
medical conditions, integrated care can lower costs
through reduced hospitalization rates, inpatient days,
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and emergency-room use [56]. We will assess changes in
the healthcare services provided to patients by collecting
healthcare utilization data using a combination of elec-
tronic health records and self-report. We will analyze
these outcomes using our multiple baseline design to de-
termine whether the costs of implementation are offset
by benefits in terms of reduced healthcare utilization.
Ethics
The study received approval from the Medical Sci-
ences Institutional Review Board at the University of
Wisconsin–Madison and is registered at ClinicalTrials.
gov (NCT01963234).
Trial status
At time of submission, the research team is entering the
pre-implementation period at the pilot clinic. Implemen-
tation of Seva with patients and staff is slated to begin
during March 2014.
Discussion
This research adds to the literature on strategies for inte-
grating addiction treatment into primary care. Our study
represents an advanced use of mobile health technology in
primary care. Seva may function as a clinician-extender
because it can provide much of the education and ongoing
therapeutic support that patients with substance use disor-
ders need, allowing clinicians to focus on providing the
primary care they are trained to deliver. Seva is unique for
giving clinicians a way to regularly monitor their patients’
progress outside the clinic through self-reported substance
use, appointment attendance, and risk/protection factors.
If implementation proves successful, the field will have
a proven strategy for implementing and sustaining an
effective technology to help address addiction treatment
and recovery support in FQHCs.
Limitations
Early experience has uncovered a host of unanswered
questions related to data sharing, security and interoper-
ability that have been difficult to resolve. For instance,
receiving IRB approval for the project was a complex
undertaking. Issues related to data sharing are proving
to be difficult to standardize from one clinic (and one
electronic health record system) to the next. Risk aversion
to data sharing may be a formidable challenge to full-scale
integration of mobile health technology in primary care.
We are currently developing a framework that describes
different arrangements for integrating mobile health data
into electronic health records, personal health records,
mobile devices, and clinical data warehouses.
Our early encounters with FQHCs have revealed
organizational differences that will be difficult to account
for statistically. For instance, one clinic routinely screens
for addiction using standardized screening instruments,
while another clinic identifies addiction through conver-
sations with patients. Such pre-implementation differ-
ences must be accounted for qualitatively to accurately
assess changes in the process of care. If implementation
is successful, Seva may help reduce variation in clinics’
approaches to core elements of addiction treatment (in-
cluding referral and treatment processes), although it is
evident that different clinics start from very different
places in important respects.
Finally, the patient-level RCTs that form the evidence
base for Seva did not include measures of healthcare
utilization (e.g., ER visits). As we shift towards an
organization-level focus in this study of implementa-
tion, we seek to understand whether Seva might help
patients access health resources more predictably and
cost-efficiently. We do not, however, have direct evi-
dence from previous RCTs to support the hypothesis
that Seva will reduce healthcare utilization, and analyses
related to healthcare utilization should be considered
exploratory. Likewise, other outcomes included in our
evaluation (for example, quality of life) were unmeas-
ured in the previous RCTs that evaluated TES and A-
CHESS. We added these measures after consulting the
RE-AIM model dimension checklist (available at www.
re-aim.hnfe.vt.edu).
Conclusion
Developing an effective technology for the treatment
and continuing care of substance use disorders, and dis-
seminating the technology widely and efficiently, is a
matter of urgency given the profound costs of SUDs. Al-
though evidence shows that treatment for substance use
disorders has wide-ranging benefits, such care — routine
for many other chronic illnesses — is rare in primary
care. A model for implementing a mobile technology to
support the treatment of substance use disorders could
provide a cost-effective means to improve the lives of
patients with drug and alcohol problems. Results of the
research will be published as they become available.
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